CMAC’s digital‑first process design is cutting pharmaceutical development timelines and material use by an order of magnitude while delivering high‑quality drug substance. By replacing trial‑and‑error experimentation with predictive modelling, it enables faster, more cost‑effective and sustainable manufacturing.

CMAC’s impurity rejection workflow provides industry with a systematic, material‑efficient approach to achieving high‑purity crystalline products in drug manufacturing. Successfully applied by Eli Lilly in clinical development, it enables robust control of impurity‑related CQAs and accelerates crystallisation process design.